Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Spartrapon Sep 11, 2020 11:31am

96 Views

Post# 31542576

RE:RE:RE:RE:RE:RE:RE:RE:Just how Massive is this News?

"I don't remember any interim results in the lipo trials of tesamorelin and there should not be any in this new trial. So this project will be an apnea dive for three years from now until results are known."

It could be a group sequential design with n readings, there will probably be at least a futility assessment, who knows? That's become quite popular and efficient of late.

Bullboard Posts

Global Tungsten Market and Supply Security